Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. That said, here are three stocks poised to prove Wall Street wrong.
Primoris (PRIM)
Consensus Price Target: $124.67 (1.5% implied return)
Listed on the NASDAQ in 2008, Primoris (NYSE: PRIM) builds, maintains, and upgrades infrastructure in the utility, energy, and civil construction industries.
Why Are We Positive On PRIM?
- Impressive 15.9% annual revenue growth over the last five years indicates it’s winning market share this cycle
- Demand is greater than supply as the company’s 159% average backlog growth over the past two years shows it’s securing new contracts and accumulating more orders than it can fulfill
- Earnings per share have massively outperformed its peers over the last two years, increasing by 28.6% annually
Primoris’s stock price of $122.80 implies a valuation ratio of 26.7x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Incyte (INCY)
Consensus Price Target: $81.55 (-5.3% implied return)
Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ: INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics for cancer and inflammatory diseases.
Why Do We Like INCY?
- Offerings and unique value proposition resonate with customers, as seen in its above-market 14.2% annual sales growth over the last two years
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 105% exceeded its revenue gains over the last five years
- Free cash flow margin grew by 6.2 percentage points over the last five years, giving the company more chips to play with
At $86.10 per share, Incyte trades at 14.1x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free.
Western Alliance Bancorporation (WAL)
Consensus Price Target: $97.80 (9.3% implied return)
Operating through five distinct regional banking divisions across the western United States, Western Alliance Bancorporation (NYSE: WAL) provides commercial banking, treasury management, mortgage services, and specialized financial solutions through its banking divisions and subsidiaries.
Why Do We Love WAL?
- Impressive 18.9% annual net interest income growth over the last five years indicates it’s winning market share this cycle
- Earnings per share grew by 11.6% annually over the last five years and trumped its peers
- Annual tangible book value per share growth of 15% over the past five years was outstanding, reflecting strong capital accumulation this cycle
Western Alliance Bancorporation is trading at $89.50 per share, or 1.3x forward P/B. Is now the time to initiate a position? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
